AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2021
Sep 2, 2021
30016_dirs_2021-09-02_896f654b-910e-41fc-9fb2-1efab5452873.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-08-31
Reporting Person: Turner Kathy V (Senior Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-31 | Common Stock | M | 1256 | $79.54 | Acquired | 4131.3869 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-31 | Incentive Stock Option (right-to-buy) | $79.54 | M | 1256 | Disposed | 2025-02-13 | Common Stock (1256) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 100 | Indirect |
Footnotes
F1: The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
F2: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 628 shares on February 14, 2020, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F3: Not applicable.